Arcus BiosciencesRCUS
Recorded

Arcus Biosciences Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration26 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Faisal KhurshidSenior Biotech Analyst

Hey, good afternoon. Hey, good afternoon, everyone. Thank you to those of you in the room, as well as those of you dialed in. My name is Faisal Khurshid, Senior Biotech Analyst at Jefferies. Really pleased to have with us today the management team of Arcus Biosciences. We got Terry and Bob on stage with me. A lot to talk through. You guys got a ton of data recently, a lot more coming up. Terry, can I pass it to you to introduce the company?

Terry RosenCEO

Sure. I'll try to do this quickly because I know we want to focus on these new data. But since there may be some people new to Arcus, I'm just going to give you a brief overview of the company, kind of bringing you from the founding of the company up until today. Arcus was founded roughly 10 years ago. Our focus has been really on small molecule drug discovery. We tend to play where there's strong biological validation, but for one reason or another, there's not a great molecule. Casdatifan really fits right down the middle there. If you look at, fast-forward to where we are now, we have a portfolio of programs, a lot of them in the immunology area. They fit that general paradigm of a great molecule, highly validated target.

Terry RosenCEO

We have a readout coming, an interim analysis of our phase III program for a drug called quemliclustat in frontline pancreatic cancer that's going to read out later this quarter. The quarter's almost over, so we'll be there shortly. Really the focus of the company is casdatifan. That's where our resources are, whether they're people, dollars, or studies. We look at casdatifan as a huge opportunity. It's a two-horse race, and in some cases, it's only a one-horse race. Basically, there's one other molecule, it's belzutifan. The reason that there's only two molecules, it comes a little bit to what I was saying about the focus of the company. HIF-2, which is the target for this molecule, is a very difficult target.

Terry RosenCEO

In fact, to give you a bit of perspective in history, the original work that informed what became belzutifan was done at University of Texas Southwestern. They solved a structure for what was, in the past, thought to be an undruggable target, HIF-2α. Then Peloton was formed, they came up with this drug, belzutifan, and Merck acquired belzutifan. Belzutifan has a primary limitation, and that's that it has absorption-limited pharmacokinetics. It's very hard to sort of get all the other right things from a drug perspective and get that piece fixed. Casdatifan really addressed that. We showed in a number of ways, including a lot of this is in a recent Nature publication, how much better casdatifan is at inhibiting HIF-2α. It's most notably, you can see that when you look at the biomarker data for HIF-2α inhibition in a human.

Terry RosenCEO

So, if you compare what casdatifan does versus what belzutifan does, basically, casdatifan can hammer this target out past a year, and belzutifan essentially loses the majority of effect sometime between one and 13 weeks. We have shown in a number of studies that casdatifan looks now better clinically, and it can be tied back to that biomarker data and those PK advantages. To just summarize the recent data that we will be getting into much more deeply today, we have shown data in the frontline, where basically we are going against the standard of care that will be ipi-nivo. We have shown data in the second line, where the standard of care is cabozantinib. We have shown data in the late line, where basically we are looking at monotherapy data right now, and we will be doing a combination study.

Terry RosenCEO

Across those lines of therapy, whether you are looking at rate of primary progression, whether you are looking at response rate, whether you are looking at PFS, and now most recently, overall survival. Overall survival is an endpoint on which Merck has not hit in any of three trials, and the data we have just shown gives us good reason to believe, and I think the clinical community, that we will be able to show an overall survival advantage in every line of therapy, and in fact, address what are the limitations of the standard of care in each line of therapy. We think this is a $5 billion-$10 billion drug that will be able to be used in consecutive therapies. There has been no evidence of resistance development. So, patient, not only will you have these advantages, but you will have a very long duration of therapy. We are well capitalized. The cash that we have takes us into 2029.

Terry RosenCEO

That is on the other side of our initial registrational trials reading out. Our first registrational trial with casdatifan is called PEAK-1. We expect it to be fully enrolled within the next month or two. Our second registrational trial, which is about to start by the end of this year, that is really our brass ring because that is the frontline. We have shown advantages in our early data. That is about to start. I will stop there and take questions.

Faisal KhurshidSenior Biotech Analyst

Yeah, let us start on, PEAK-1, you are running that study. Remind us the design of the study, that second line RCC comparing to cabo monotherapy, right? The comp here for belzutifan is LITESPARK-011 that we recently saw some more data for. It is a pretty nuanced kind of concept of comparing your ARC-20, your early-stage kind of second line RCC dataset to LITESPARK-011. Can you walk us through the nuances of how to compare those two datasets? Because, at a top-line level, they both land at about 14 and a half months, but it is different for reasons I think you guys explained well, so I want to give you the opportunity to- Yeah, sure.

Bob GoeltzCFO

I think when you think about doing the cross-trial comparison, you have to think about probably a couple of things. Most notably is the patient population, and a large portion of the difference between the patient populations is due to when the studies were enrolled in the global footprint from those studies. In the registrational study, LITESPARK-011, that Merck conducted, the study structure, first of all, was somewhat unusual. It was lenvatinib plus belzutifan versus cabozantinib, which is the widely accepted standard of care in the second line. As a result, that study precluded prior treatment with both of those TKIs, lenvatinib, as well as cabozantinib, which is a large portion of what frontline patients receive today.

Bob GoeltzCFO

The other piece of their study probably that was more due to the timing of it and the global footprint of the study was that they enrolled a very large percentage of the patients that had received older generation TKIs. These are drugs like sunitinib and pazopanib that are no longer standard of care in the U.S. or in most major markets. A study that would be enrolled today, like our phase II ARC-20 study, would not see significant representation from those patients. So, why is that important? Those patients generally tend to perform well on subsequent TKI current generation therapy. In the LITESPARK-011 study, now we've seen some sub-patient population analyses that Merck shared at ESMO, which showed that those patients outperformed the remainder of the patients in the study, and in fact, they were about a third of the patient population.

Bob GoeltzCFO

We don't expect to see those patients in our study, and therefore, we would expect a different performance.

Faisal KhurshidSenior Biotech Analyst

Got it. To kind of put it at a high level, essentially, they selected for patients who hadn't been treated with the optimal TKI, so they saw better efficacy when they're looking at their TKI combo. Is that a fair way to simplify it?

Terry RosenCEO

I think the way to simplify it is, the patient population that we're running in looks very much like the real-world patient population. 60% of the patients that come into that are going to have received a second-generation TKI. Those patients perform more poorly on what's the control arm for both our study and the Merck study. In fact, the subpopulation data that Bob discussed showed exactly that. The totality of our data suggests that we're going to have two advantages relative to what belzutifan/lenva showed. First of all, we're going to give those patients that get a second generation that would otherwise do poorly, they do as well or better on cabozantinib.

Terry RosenCEO

The second piece is that for the first time, we showed data not only in our late line, but in this study in ARC-20, that suggests a very strong probability, and in fact, I'd say virtual certainty, that we're going to show an overall survival advantage. That's viewed as something that would essentially cannibalize the entire second-line market. We'll have both that OS advantage that Merck didn't show, and then we'll have the advantage in that 60% of the patients that would otherwise be underserved by a subsequent TKI therapy, that cabozantinib will serve well.

Faisal KhurshidSenior Biotech Analyst

Yeah, makes sense. I understand the differences that you're pointing out between ARC-20 and LITESPARK-011 with respect to prior TKI exposure. How would you recommend thinking about the comparability of those patient populations with respect to other factors like high risk versus lower risk, prior lines of therapy, things like that?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day